<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957370</url>
  </required_header>
  <id_info>
    <org_study_id>HS#2014-1758</org_study_id>
    <nct_id>NCT02957370</nct_id>
  </id_info>
  <brief_title>Molecular Biosensors for Detection of Bladder Cancer</brief_title>
  <official_title>Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project focuses on developing specific and sensitive detectors of biomarker-based
      signatures associated with diagnosed and recurrent bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The focus of this research is to discover urinary biomarker(s) that is distinct to bladder
      cancer, while developing molecular sensors that can detect the urinary anomalies. By applying
      in vitro selection techniques, both entities (biomarker discovery and sensor development)
      will be done simultaneously.

      All patients with bladder cancer diagnosis undergoing transurethral resection bladder tumor
      (TURBT), those under surveillance for bladder cancer and patients presenting with microscopic
      and visible (gross) hematuria will be invited to participate in the study. Patients will
      undergo a standard of care evaluation as previously described (upper urinary tract imaging,
      cystouretheroscopy and urine testing with urinalysis, culture and cytology).

      Urine samples (10 mL) for the study will be collected prior to initial cystoscopy and/or
      TURBT. The specimen will be barcoded and tracked by the UC Irvine Health software. Barcode
      encoding will ensure that the identity of the patient and his/her clinical outcome will not
      be available to the researchers for a blinded trial.

      Patients involved in this study will only provide his or her urine for fundamental science
      research; beyond that, standard of care will be provided for the patients. With respect to
      the collected urine, it will be used as a medium for phage and aptamer production in an in
      vitro fashion. The generated molecular probes will be use to assess and elucidate biomarkers
      present for individuals with bladder cancer.

      100 patients who are being monitored for bladder cancer will be the experimental group to
      test the electro-phage and aptamer approach to following bladder cancer biomarkers.
      Additionally, 100 patients being treated for hematuria will provide a negative control to
      provide data from testing for biomarkers in patients being treated for other diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary &quot;Fingerprint&quot; for Urinary Bladder Neoplasms</measure>
    <time_frame>Four Years</time_frame>
    <description>A representative sequence from each class of the selected population will be synthesized and the fundamental properties for each aptamer sequences such as dissociation constant, switching performance, sensitivity, selectivity, and detection range will be measured using a Förster resonance energy transfer (FRET) system.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Urinary Bladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>Diagnosed Urinary Bladder Neoplasms</arm_group_label>
    <description>Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Urinary Bladder Neoplasms</arm_group_label>
    <description>Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited at the University of California, Irvine Medical Center
        Douglas Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years old

          -  Patients with diagnosed bladder cancer, undergoing transurethral resection bladder
             tumor (TRUBT), or under surveillance (within 2 years) for recurrent bladder cancer

          -  Patients with microscopic and macroscopic hematuria

          -  Willing and able to consent

        Exclusion Criteria:

          -  Patients &lt;18 years old

          -  Patients who are not able to give consent for study

          -  Patients with urinary diversions

          -  Patients who have had a recent percutaneous or endoscopic procedures for upper tract
             diseases such as stones or other conditions

          -  Patients who have ureteral stents placed for upper urinary tract obstruction

          -  Patients with recent trauma in kidney, bladder or perineal area, which may be the
             cause of hematuria

          -  Minors will be excluded from this study because ureteral stent placement is usually
             performed in adult patients. Additionally, minors are treated at CHOC Hospital, and
             not UCIMC.

          -  Women who are pregnant are excluded from this study since surgical treatments are not
             typically performed on pregnant women. Watchful waiting is the preferred approach for
             pregnant women. Furthermore, this research does not directly benefit the pregnant
             woman or fetus, and biomedical knowledge can be obtained using subjects who are not
             pregnant. Therefore, per the federal regulations, pregnant women will be excluded from
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Landman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor B Huynh, BS</last_name>
    <phone>714-456-8176</phone>
    <email>vbhuynh@uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Huynh, BS</last_name>
      <phone>714-456-8176</phone>
      <email>vbhuynh@uci.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kay, B. K. (1996) Table 15. M13 Stability and Instability, In Phage Display of Peptides and Proteins: A Laboratory Manual (Kay, B. K., Winter, J., McCafferty, J., Ed.), p 337, Academic Press, San Diego.</citation>
  </reference>
  <reference>
    <citation>Mohan K, Donavan KC, Arter JA, Penner RM, Weiss GA. Sub-nanomolar detection of prostate-specific membrane antigen in synthetic urine by synergistic, dual-ligand phage. J Am Chem Soc. 2013 May 22;135(20):7761-7. doi: 10.1021/ja4028082. Epub 2013 May 13.</citation>
    <PMID>23614709</PMID>
  </reference>
  <reference>
    <citation>Arter JA, Diaz JE, Donavan KC, Yuan T, Penner RM, Weiss GA. Virus-polymer hybrid nanowires tailored to detect prostate-specific membrane antigen. Anal Chem. 2012 Mar 20;84(6):2776-83. doi: 10.1021/ac203143y. Epub 2012 Mar 7.</citation>
    <PMID>22339784</PMID>
  </reference>
  <reference>
    <citation>Arter JA, Taggart DK, McIntire TM, Penner RM, Weiss GA. Virus-PEDOT nanowires for biosensing. Nano Lett. 2010 Dec 8;10(12):4858-62. doi: 10.1021/nl1025826. Epub 2010 Nov 1.</citation>
    <PMID>21038915</PMID>
  </reference>
  <reference>
    <citation>Diaz JE, Yang LM, Lamboy JA, Penner RM, Weiss GA. Synthesis of a virus electrode for measurement of prostate specific membrane antigen. Methods Mol Biol. 2009;504:255-74. doi: 10.1007/978-1-60327-569-9_16.</citation>
    <PMID>19159102</PMID>
  </reference>
  <reference>
    <citation>Donavan KC, Arter JA, Weiss GA, Penner RM. Virus-poly(3,4-ethylenedioxythiophene) biocomposite films. Langmuir. 2012 Aug 28;28(34):12581-7. doi: 10.1021/la302473j. Epub 2012 Aug 16.</citation>
    <PMID>22856875</PMID>
  </reference>
  <reference>
    <citation>Weiss GA, Penner RM. The Promise of Phage Display: Customized Affinity and Specificity. Anal Chem. 2008 May 1;80(9):3082-3089. doi: 10.1021/ac086009h.</citation>
    <PMID>28193009</PMID>
  </reference>
  <reference>
    <citation>Yang LM, Diaz JE, McIntire TM, Weiss GA, Penner RM. Direct electrical transduction of antibody binding to a covalent virus layer using electrochemical impedance. Anal Chem. 2008 Aug 1;80(15):5695-705. doi: 10.1021/ac8008109. Epub 2008 Jul 1.</citation>
    <PMID>18590279</PMID>
  </reference>
  <reference>
    <citation>Yang LM, Tam PY, Murray BJ, McIntire TM, Overstreet CM, Weiss GA, Penner RM. Virus electrodes for universal biodetection. Anal Chem. 2006 May 15;78(10):3265-70.</citation>
    <PMID>16689525</PMID>
  </reference>
  <reference>
    <citation>Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70. Review.</citation>
    <PMID>10647931</PMID>
  </reference>
  <reference>
    <citation>Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brücher B, Stojadinovic A, Man YG. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer. 2014 Jan 1;5(1):3-24. doi: 10.7150/jca.7709. Review.</citation>
    <PMID>24396494</PMID>
  </reference>
  <reference>
    <citation>Romero Otero J, Garcia Gomez B, Campos Juanatey F, Touijer KA. Prostate cancer biomarkers: an update. Urol Oncol. 2014 Apr;32(3):252-60. doi: 10.1016/j.urolonc.2013.09.017. Epub 2014 Feb 1. Review.</citation>
    <PMID>24495450</PMID>
  </reference>
  <reference>
    <citation>Guan W, Duan X, Reed MA. Highly specific and sensitive non-enzymatic determination of uric acid in serum and urine by extended gate field effect transistor sensors. Biosens Bioelectron. 2014 Jan 15;51:225-31. doi: 10.1016/j.bios.2013.07.061. Epub 2013 Aug 7.</citation>
    <PMID>23968728</PMID>
  </reference>
  <reference>
    <citation>Yang LM, Diaz JE, McIntire TM, Weiss GA, Penner RM. Covalent virus layer for mass-based biosensing. Anal Chem. 2008 Feb 15;80(4):933-43. doi: 10.1021/ac071470f. Epub 2008 Jan 17.</citation>
    <PMID>18198846</PMID>
  </reference>
  <reference>
    <citation>Brigati JR, Petrenko VA. Thermostability of landscape phage probes. Anal Bioanal Chem. 2005 Jul;382(6):1346-50. Epub 2005 Jun 18.</citation>
    <PMID>15965686</PMID>
  </reference>
  <reference>
    <citation>Nanduri V, Sorokulova IB, Samoylov AM, Simonian AL, Petrenko VA, Vodyanoy V. Phage as a molecular recognition element in biosensors immobilized by physical adsorption. Biosens Bioelectron. 2007 Jan 15;22(6):986-92. Epub 2006 May 30.</citation>
    <PMID>16730970</PMID>
  </reference>
  <reference>
    <citation>Závada J, Závadová Z, Zat'ovicová M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer. 2003 Sep 15;89(6):1067-71.</citation>
    <PMID>12966427</PMID>
  </reference>
  <reference>
    <citation>Huang S, Rhee E, Patel H, Park E, Kaswick J. Urinary NMP22 and renal cell carcinoma. Urology. 2000 Feb;55(2):227-30.</citation>
    <PMID>10688084</PMID>
  </reference>
  <reference>
    <citation>Kaya K, Ayan S, Gokce G, Kilicarslan H, Yildiz E, Gultekin EY. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma. Scand J Urol Nephrol. 2005;39(1):25-9.</citation>
    <PMID>15764267</PMID>
  </reference>
  <reference>
    <citation>Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol. 2005 Jul;174(1):64-8.</citation>
    <PMID>15947579</PMID>
  </reference>
  <reference>
    <citation>van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005 Jun;47(6):736-48. Epub 2005 Mar 23. Review.</citation>
    <PMID>15925067</PMID>
  </reference>
  <reference>
    <citation>Majumdar S, Hajduczki A, Mendez AS, Weiss GA. Phage display of functional, full-length human and viral membrane proteins. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5937-40. doi: 10.1016/j.bmcl.2008.07.051. Epub 2008 Jul 17.</citation>
    <PMID>18667306</PMID>
  </reference>
  <reference>
    <citation>Levin AM, Weiss GA. Optimizing the affinity and specificity of proteins with molecular display. Mol Biosyst. 2006 Jan;2(1):49-57. Epub 2005 Nov 8. Review.</citation>
    <PMID>16880922</PMID>
  </reference>
  <reference>
    <citation>Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5981-6. Epub 2005 Apr 18.</citation>
    <PMID>15837926</PMID>
  </reference>
  <reference>
    <citation>Hajduczki A, Majumdar S, Fricke M, Brown IA, Weiss GA. Solubilization of a membrane protein by combinatorial supercharging. ACS Chem Biol. 2011 Apr 15;6(4):301-7. doi: 10.1021/cb1001729. Epub 2011 Jan 14.</citation>
    <PMID>21192634</PMID>
  </reference>
  <reference>
    <citation>Lunder, M., Bratkovic, T., Anderluh, G., Strukelj, B., and Kreft, S. (2008) Affinity ranking of phage-displayed peptides: Enzyme-linked immunosorbent assay versus surface plasmon resonance, Acta Chimica Slovenica 55, 233-235.</citation>
  </reference>
  <reference>
    <citation>Murase K, Morrison KL, Tam PY, Stafford RL, Jurnak F, Weiss GA. EF-Tu binding peptides identified, dissected, and affinity optimized by phage display. Chem Biol. 2003 Feb;10(2):161-8.</citation>
    <PMID>12618188</PMID>
  </reference>
  <reference>
    <citation>Weiss GA, Watanabe CK, Zhong A, Goddard A, Sidhu SS. Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8950-4.</citation>
    <PMID>10908667</PMID>
  </reference>
  <reference>
    <citation>Avrantinis SK, Stafford RL, Tian X, Weiss GA. Dissecting the streptavidin-biotin interaction by phage-displayed shotgun scanning. Chembiochem. 2002 Dec 2;3(12):1229-34.</citation>
    <PMID>12465031</PMID>
  </reference>
  <reference>
    <citation>Mohan K, Weiss GA. Dual genetically encoded phage-displayed ligands. Anal Biochem. 2014 May 15;453:1-3. doi: 10.1016/j.ab.2014.02.025. Epub 2014 Mar 4.</citation>
    <PMID>24607794</PMID>
  </reference>
  <reference>
    <citation>Levin AM, Murase K, Jackson PJ, Flinspach ML, Poulos TL, Weiss GA. Double barrel shotgun scanning of the caveolin-1 scaffolding domain. ACS Chem Biol. 2007 Jul 20;2(7):493-500. Epub 2007 Jun 29.</citation>
    <PMID>17602618</PMID>
  </reference>
  <reference>
    <citation>Levin AM, Coroneus JG, Cocco MJ, Weiss GA. Exploring the interaction between the protein kinase A catalytic subunit and caveolin-1 scaffolding domain with shotgun scanning, oligomer complementation, NMR, and docking. Protein Sci. 2006 Mar;15(3):478-86. Epub 2006 Feb 1.</citation>
    <PMID>16452625</PMID>
  </reference>
  <reference>
    <citation>Nutiu R, Li Y. In vitro selection of structure-switching signaling aptamers. Angew Chem Int Ed Engl. 2005 Feb 4;44(7):1061-5.</citation>
    <PMID>15643624</PMID>
  </reference>
  <reference>
    <citation>Oh SS, Plakos K, Lou X, Xiao Y, Soh HT. In vitro selection of structure-switching, self-reporting aptamers. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14053-8. doi: 10.1073/pnas.1009172107. Epub 2010 Jul 26.</citation>
    <PMID>20660786</PMID>
  </reference>
  <reference>
    <citation>Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990 Aug 3;249(4968):505-10.</citation>
    <PMID>2200121</PMID>
  </reference>
  <reference>
    <citation>Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990 Aug 30;346(6287):818-22.</citation>
    <PMID>1697402</PMID>
  </reference>
  <reference>
    <citation>Liu J, Cao Z, Lu Y. Functional nucleic acid sensors. Chem Rev. 2009 May;109(5):1948-98. doi: 10.1021/cr030183i. Review.</citation>
    <PMID>19301873</PMID>
  </reference>
  <reference>
    <citation>Zhao W, Ali MM, Aguirre SD, Brook MA, Li Y. Paper-based bioassays using gold nanoparticle colorimetric probes. Anal Chem. 2008 Nov 15;80(22):8431-7. doi: 10.1021/ac801008q. Epub 2008 Oct 11.</citation>
    <PMID>18847216</PMID>
  </reference>
  <reference>
    <citation>Wood JB, Szyndler MW, Halpern AR, Cho K, Corn RM. Fabrication of DNA microarrays on polydopamine-modified gold thin films for SPR imaging measurements. Langmuir. 2013 Aug 27;29(34):10868-73. doi: 10.1021/la402425n. Epub 2013 Aug 15.</citation>
    <PMID>23902428</PMID>
  </reference>
  <reference>
    <citation>Toma M, Loget G, Corn RM. Flexible Teflon nanocone array surfaces with tunable superhydrophobicity for self-cleaning and aqueous droplet patterning. ACS Appl Mater Interfaces. 2014 Jul 23;6(14):11110-7. doi: 10.1021/am500735v. Epub 2014 Apr 1.</citation>
    <PMID>24654844</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Jaime Landman</investigator_full_name>
    <investigator_title>Dr. Jaime Landman M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

